Key Takeaway: CG Oncology is set to participate in the AUA 2025 PIVOT-006 Learning Lab. The company has recently reported positive results from its CORE-1008 Phase 2 trial, which evaluates a new intravesical combination therapy. Additionally, CG Oncology is involved in various upcoming investor conferences and has announced fellowship award recipients for NMIBC research.
Price reaction · baseline $26 (2025-06-02T13:59:00.000Z) · hit during market hours · 4 other CGON headline(s) in the window, move may be shared
day 0 close · peak
+2.3%
Market Sentiment Analysis
POSITIVE FACTORS
CG Oncology is actively participating in multiple conferences.
Positive results reported from CORE-1008 trial.
Recognition of research fellowship award recipients.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+139%
120-day peak, hindsight
Typical move
6.3%
average across 5 past catalysts
Cash runway
~66 mo
Minimal dilution risk
Lead asset
CG0070
Phase 2 · Non Muscle Invasive Bladder Cancer
Full Press Release Details
by admin | Jun 2, 2025 | congress-hub-presentations
Recent Posts
• CUA 2026 – BOND-003 Cohort C Podium
• CG Oncology to Present at Upcoming Investor Conferences in June
• SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
• CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients
• AUA 2026 – CORE 008 Cohort CX Presentation
Recent Comments
Frequently Asked Questions
What is the AUA 2025 PIVOT-006 Learning Lab?
The AUA 2025 PIVOT-006 Learning Lab is an event where CG Oncology will present findings.
What recent results did CG Oncology report?
CG Oncology reported positive results from the CORE-1008 Phase 2 trial.
What is the focus of the CORE-1008 trial?
The CORE-1008 trial evaluates an intravesical combination therapy for high-risk patients.
What other events is CG Oncology participating in?
CG Oncology is also participating in various investor conferences in June.